Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits.

McGuire, Darren K; Inzucchi, Silvio E; Johansen, Odd Erik; Rosenstock, Julio; George, Jyothis T; Marx, Nikolaus

McGuire, Darren K; Inzucchi, Silvio E; Johansen, Odd Erik; Rosenstock, Julio; George, Jyothis T; Marx, Nikolaus.

Afiliación

McGuire DK; University of Texas Southwestern Medical Center, Dallas, TX, USA.
Inzucchi SE; Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
Johansen OE; Clinical Development, Therapeutic Area Cardiometabolism, Boehringer Ingelheim, Hagaløkkveien 26, 1373, Asker, Norway. Odd_erikj@hotmail.com.
Rosenstock J; Dallas Diabetes Research Center at Medical City and University of Texas, Southwestern Medical Center, Dallas, USA.
George JT; Clinical Development, Therapeutic Area Cardiometabolism, Boehringer Ingelheim, Ingelheim, Germany.
Marx N; Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.

J Pharm Policy Pract ; 14(1): 35, 2021 Apr 15.

Article en En | MEDLINE | ID: mdl-33858511

Palabras clave

Bias; Cardiovascular outcome trials; Epidemiology; Medication; Risk reduction; SGLT-2 inhibitor; Type 2 diabetes

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: J Pharm Policy Pract Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: J Pharm Policy Pract Año: 2021 Tipo del documento: Article